Cyrus Therapeutics
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $11M
Investors
- 7
About Cyrus Therapeutics
Based in Seoul, South Korea, and founded in 2019 by Byong-Moon Kim (CEO), Cyrus Therapeutics, Inc. operates as a biotechnology company specializing in developing a new anticancer drug for a resistance-causing target. In January 2022, Cyrus Therapeutics, Inc. Cyrus Therapeutics, Inc. provides medicine developers focusing on chronic or life-threatening diseases with high unmet needs. Furthermore, the company's technology employs a variety of new drug modalities, including traditional small molecule inhibitors and the primary focus is on developing small molecule medicines to conquer unsolvable cancer targets, as well as expanding new chemical spaces such as targeted protein degraders (TPDs) and antibody recruiting molecules (ARMs). The investment which was held on January 2022, plans to help Cyrus Therapeutics, Inc. in its pipeline development-related clinical trials and secure additional pre-clinical tasks by next year.
Who invested in Cyrus Therapeutics
7 investors across 2 rounds
See all investors in Cyrus Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cyrus Therapeutics
Who invested in Cyrus Therapeutics?
Cyrus Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cyrus Therapeutics raised?
Cyrus Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cyrus Therapeutics last raise money?
Cyrus Therapeutics's most recent round on record is a Series B, in Jan 2022.
What does Cyrus Therapeutics do?
Based in Seoul, South Korea, and founded in 2019 by Byong-Moon Kim (CEO), Cyrus Therapeutics, Inc.
Where is Cyrus Therapeutics headquartered?
Cyrus Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like Cyrus Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Cyrus Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Cyrus Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.